DE214555T1 - Fusionspolypeptid mit antigener wirkung. - Google Patents

Fusionspolypeptid mit antigener wirkung.

Info

Publication number
DE214555T1
DE214555T1 DE198686111884T DE86111884T DE214555T1 DE 214555 T1 DE214555 T1 DE 214555T1 DE 198686111884 T DE198686111884 T DE 198686111884T DE 86111884 T DE86111884 T DE 86111884T DE 214555 T1 DE214555 T1 DE 214555T1
Authority
DE
Germany
Prior art keywords
polypeptide antigen
gene
recombinant plasmid
adult
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE198686111884T
Other languages
English (en)
Inventor
Seiga Sagamihara-Shi Kanagawa-Ken Itoh
Tetsuro Kuga
Susumu Machida-Shi Tokyo Sekine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of DE214555T1 publication Critical patent/DE214555T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (21)

  1. 0.21 A
    u.Z.: U 818 EP
    EP 86 11 1884.2
    KYOWA HAKKO KOGYO K.K.
    Patentansprüche
    (deutsche übersetzung gem. Art. 67 EPÜ)
    1 . Fusions-Polypeptidantigen, dadurch gekennzeichnet, daß es mindestens zwei miteinander fusionierte Polypeptidantigene aufweist (nachstehend bezeichnet als "Hybrid-Polypeptidantigen").
  2. 2. Polypeptid nach Anspruch 1, dadurch gekennzeichnet, daß die Polypeptidantigene von einem Erwachsenen-T-Zelleukämievirus-Polypeptidantigen abgeleitet sind.
  3. 3. Polypeptid nach Anspruch 2, dadurch gekennzeichnet, daß das Erwachsenen-T-Zelleukämievirus-Polypeptidantigen ein vom gag-Gen oder von einem Teil dieses Gens codiertes Polypeptidantigen ist.
  4. 4. Polypeptid nach Anspruch 2, dadurch gekennzeichnet, daß das Erwachsenen-T-Zelleukämievirus-Polypeptidantigen ein vom env-Gen oder von einem Teil dieses Gens codiertes Polypeptidantigen ist.
  5. 5. Hybrid-Polypeptidantigen nach Anspruch 1, dadurch gekennzeichnet, daß es ein Fusions-Polypeptidantigen ist, in dem ein vom gag-Gen des Erwachsenen-T-Zelleukämievirus oder von einem Teil dieses Gens codiertes Polypeptidantigen mit einem vom env-Gen des Erwachsenen-T-Zelleukämievirus oder von einem Teil dieses Gens codiertem Polypeptidantigen fusioniert ist.
  6. 6. Rekombinantes Plasmid, dadurch gekennzeichnet, daß es
    02U555
    ein für ein Hybrid-Polypeptidantigen codierendes DNA-Fragment enthält.
  7. 7. Rekombinantes Plasmid nach Anspruch 6, dadurch gekennzeichnet, daß das für das Polypeptidantigen codierende DNA-Fragment von einem für ein Erwachsenen-T-Zelleukämievirus-Antigen codierenden DNA-Fragment abgeleitet ist.
  8. 8. Rekombinantes Plasmid nach Anspruch 7, dadurch gekenn- IQ zeichnet, daß das für das Erwachsenen-T-Zelleukämievirus-Antigen codierende DNA-Fragment das gag-Gen oder ein Teil dieses Gens ist.
  9. 9. Rekombinantes Plasmid nach Anspruch 7, dadurch gekenn-]_5 zeichnet, daß das für das Erwachsenen-T-Zelleukämievirus-Antigen codierende DNA-Fragment das en&ngr;-Gen oder ein Teil dieses Gens ist.
  10. 10. Rekombinantes Plasmid nach Anspruch 7, dadurch gekennzeichnet, daß es ein für ein Hybrid-Polypeptidantigen codierendes DNA-Fragment enthält, in dem ein vom gag-Gen des Erwachsenen-T-Zelleukämievirus oder von einem Teil dieses Gens codiertes Polypeptidantigen mit einem vom env-Gen des Erwachsenen-T-Zelleukämievirus oder von einem Teil dieses Gens codiertem Polypeptidantigen fusioniert ist.
  11. 11. Rekombinantes Plasmid nach Anspruch 6, dadurch gekennzeichnet , daß es einen Tryptophan-Promotor enthält.
  12. oQ 12. Rekombinantes Plasmid nach Anspruch 11, dadurch gekennzeichnet, daß es pETl7 ist.
  13. 13. Verfahren zur Herstellung eines Hybrid-Polypeptidantigens, dadurch gekennzeichnet, daß man in einem Nährmedium g,- einen Mikroorganismus züchtet, der ein rekombinantes Plasmid enthält, in das ein für das Hybrid-Polypeptidantigen codie-
    Q2H555
    rendes DNA-Fragment eingebaut ist, das Hybrid-Polypeptidantigen sich im Nährmedium ansammeln läßt und aus diesem das Hyforid-Polypeptidantigen wiedergewinnt.
  14. 14. Verfahren nach Anspruch 13, dadurch gekennzeichnet, daß das rekombinante Plasmid ein für ein Erwachsenen-T-Zelleukämievirus-Polypeptidantigen codierendes DNA-Fragment enthält.
  15. 15. Verfahren nach Anspruch 14, dadurch gekennzeichnet, daß IQ das rekombinante Plasmid einen Tryptophan-Promotor enthält.
  16. 16. Verfahren nach Anspruch 15, dadurch gekennzeichnet, daß das rekombinante Plasmid pETI7 ist.
  17. 2g 17. Verfahren nach Anspruch 13, dadurch gekennzeichnet, daß der Mikroorganismus zur Art Escherichia coli gehört.
  18. 18. Mikroorganismus, dadurch gekennzeichnet, daß er ein rekombinantes Plasmid trägt, in das ein für ein Hybrid-Poly-
    2Q peptidantigen codierendes DNA-Fragment eingebaut ist.
  19. 19. Mikroorganismus nach Anspruch 18, dadurch gekennzeichnet, daß das rekombinante Plasmid ein für ein Erwachsenen-T-Zelleukämievirus-Polypeptidantigen codierendes DNA-Fragment enthält.
  20. 20. Mikroorganismus nach Anspruch 18, dadurch gekennzeichnet, daß das rekombinante Plasmid einen Tryptophan-Protomor enthält.
  21. 21. Verwendung eines Polypeptids nach einem der Ansprüche
    1 bis 5 bei einer Serum-Diagnose zum Nachweis von anti-ATLA-Antikörpern.
DE198686111884T 1985-08-28 1986-08-27 Fusionspolypeptid mit antigener wirkung. Pending DE214555T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60188868A JP2564268B2 (ja) 1985-08-28 1985-08-28 融合抗原ポリペプチド

Publications (1)

Publication Number Publication Date
DE214555T1 true DE214555T1 (de) 1987-09-24

Family

ID=16231274

Family Applications (2)

Application Number Title Priority Date Filing Date
DE198686111884T Pending DE214555T1 (de) 1985-08-28 1986-08-27 Fusionspolypeptid mit antigener wirkung.
DE8686111884T Expired - Lifetime DE3671244D1 (de) 1985-08-28 1986-08-27 Fusionspolypeptid mit antigener wirkung.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE8686111884T Expired - Lifetime DE3671244D1 (de) 1985-08-28 1986-08-27 Fusionspolypeptid mit antigener wirkung.

Country Status (5)

Country Link
US (2) US4939094A (de)
EP (1) EP0214555B1 (de)
JP (1) JP2564268B2 (de)
CA (1) CA1306209C (de)
DE (2) DE214555T1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
EP0246101A3 (de) * 1986-05-14 1989-06-07 FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. Protein mit HTLV-I-antigener Aktivität und dessen Herstellung
JP2501569B2 (ja) * 1986-11-14 1996-05-29 協和醗酵工業株式会社 抗成人ｔ細胞白血病ウイルス抗体の検出法
US5614366A (en) * 1986-12-31 1997-03-25 Genelabs Technologies, Inc. HTLV-I peptide antigens and kit
US5643714A (en) * 1986-12-31 1997-07-01 Genelabs Technologies, Inc. Method and assay for HTLV
AU615670B2 (en) * 1987-09-04 1991-10-10 Murex Diagnostics Corporation Immunoassay and biological constructs for use therein
US5017687A (en) * 1988-03-10 1991-05-21 Virovahl, S.A. Peptides for the detection of HTLV-1 infection
ATE105334T1 (de) * 1988-04-22 1994-05-15 Upjohn Co Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
EP0345792A3 (de) * 1988-06-10 1991-05-02 F. Hoffmann-La Roche Ag HTLV-1/HIV-1-Fusionsproteine
CA2003383A1 (en) 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
AU5827590A (en) * 1989-06-01 1991-01-07 E.I. Du Pont De Nemours And Company Htlv-1 env gene products expressed in (e. coli)
DE69019291T2 (de) * 1989-10-23 1995-09-21 F. Hoffmann-La Roche Ag, Basel Synthetische HTLV-I Hüll-Peptide.
IE904083A1 (en) * 1989-11-13 1991-05-22 Cambridge Biotech Corp Diagnostic proteins to test for more than one antibody
DE4420742A1 (de) * 1993-10-20 1995-04-27 Boehringer Mannheim Gmbh Synthetischer Standard für Immunoassays
EP0999848B1 (de) * 1997-12-23 2007-02-21 Alexion Pharmaceuticals, Inc. Chimäre proteine zur behandlung von diabetes
US6982323B1 (en) * 1997-12-23 2006-01-03 Alexion Pharmaceuticals, Inc. Chimeric proteins for diagnosis and treatment of diabetes
CA2630341C (en) 1998-04-14 2011-07-26 Kyowa Hakko Kogyo Co., Ltd. Process for producing isoprenoid compounds by microorganisms
JP4474496B2 (ja) 1998-06-02 2010-06-02 学校法人日本大学 ＩｇＡ腎症関連ＤＮＡ
AU2001274536A1 (en) 2000-06-15 2002-01-02 Kyowa Hakko Kogyo Co. Ltd. Insulin-like growth factor-binding protein
JP3765574B2 (ja) * 2001-02-22 2006-04-12 三菱化学株式会社 逆向き反復配列を含む組み換え遺伝子及びその利用
AU2002251533B2 (en) * 2001-04-25 2006-09-28 Institut National De La Recherche Agronomique Protein involved in restoration of cytoplasmic male sterility to fertility and gene encoding the protein and gene
US20040117868A1 (en) * 2002-01-29 2004-06-17 Jun Imamura Protein participating in restoration from cytoplasmic male sterility to fertility and gene encoding the same
US6995236B2 (en) * 2001-05-08 2006-02-07 Riken Sphingomyelin detecting probe
WO2003027296A1 (fr) * 2001-09-20 2003-04-03 Plantech Research Institute Genes intervenant dans la synthese d'acide gras presentant une liaison double conjuguee trans-11-, cis-13-, et utilisation desdits genes
JP2003144141A (ja) * 2001-11-14 2003-05-20 Gencom Co ＲＮＡｉ効果が増強したＥＳ細胞
AU2003234789A1 (en) 2002-05-08 2003-11-11 Kyowa Hakko Kogyo Co., Ltd. Process for producing cytidine 5'-diphocphate choline
JP4171256B2 (ja) * 2002-07-18 2008-10-22 三菱化学株式会社 パピローマウイルスベクターを用いたＲＮＡｉ表現型を有する非ヒト哺乳動物の作製方法
CA2497338A1 (en) 2002-08-30 2004-03-18 Japan Science And Technology Corporation Method of targeted gene disruption, genome of hyperthermostable bacterium and genome chip using the same
JP2004180641A (ja) * 2002-12-06 2004-07-02 Gencom Co ＲＮＡｉ表現型を有する非ヒト哺乳動物の作製方法
US20090270314A1 (en) 2005-09-29 2009-10-29 Tohoku University Polypeptide having anti-angiogenic activity
CA2632419A1 (en) 2005-12-06 2007-06-14 Kyowa Hakko Kogyo Co., Ltd. Genetically recombinant anti-perp antibody
JP5592059B2 (ja) 2005-12-27 2014-09-17 協和発酵バイオ株式会社 Ｌ−グルタミンの製造法
CN101511870B (zh) 2006-06-06 2014-04-09 协和发酵麒麟株式会社 能够与肝素结合性表皮生长因子样生长因子结合的单克隆抗体
EP2138576A4 (de) 2007-03-16 2011-02-23 Kyowa Hakko Kirin Co Ltd Anti-claudin-4-antikörper
EP2140876A4 (de) 2007-03-29 2011-08-03 Univ Okayama Nat Univ Corp Therapeutisches mittel mit vasohibin
JP5550041B2 (ja) 2007-09-27 2014-07-16 塩野義製薬株式会社 チトクロームｐ４５０を用いたアダマンタン水酸化体の製造方法
AU2008332296A1 (en) 2007-12-05 2009-06-11 Kyowa Hakko Kirin Co., Ltd. Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
JP5425775B2 (ja) 2008-06-30 2014-02-26 協和発酵キリン株式会社 抗ｃｄ２７抗体
CN102099468B (zh) 2008-07-17 2014-01-15 协和发酵麒麟株式会社 抗-***asc氨基酸转运蛋白2(asct2)抗体
HUE029946T2 (en) 2008-12-26 2017-04-28 Kyowa Hakko Kirin Co Ltd Anti-CD4 antibody
ES2829423T3 (es) 2009-04-20 2021-05-31 Kyowa Kirin Co Ltd Anticuerpo anti-CD40 que contiene IgG2 que presenta tres mutaciones de aminoácido introducidas en el mismo
TWI629483B (zh) 2010-06-11 2018-07-11 協和醱酵麒麟有限公司 anti-TIM-3 antibody
CN103781800A (zh) 2011-06-20 2014-05-07 协和发酵麒麟株式会社 抗erbB3抗体
KR102143476B1 (ko) 2012-07-02 2020-08-12 쿄와 기린 가부시키가이샤 항ｂｍｐ９ 항체를 유효 성분으로 하는, 신장성 빈혈, 암성 빈혈 등의 빈혈에 대한 치료제
CN104884617B (zh) 2012-12-07 2019-02-19 协和发酵麒麟株式会社 抗folr1抗体
EP2913338A1 (de) 2014-02-28 2015-09-02 Roche Diagniostics GmbH Lösliche und immunoreaktive Varianten von HTLV-Antigen-Kapsid P24
JP7036386B2 (ja) 2016-03-04 2022-03-15 国立大学法人 新潟大学 変異型テトラプレニル－β－クルクメン環化酵素及びアンブレインの製造方法
US11433141B2 (en) 2016-07-26 2022-09-06 Shizuoka Prefecture Anti-B7-H4 antibody
MY190347A (en) 2016-08-10 2022-04-15 Spiber Inc Production method for insoluble recombinant protein aggregate
WO2018066558A1 (ja) 2016-10-03 2018-04-12 Ｓｐｉｂｅｒ株式会社 組換えタンパク質の精製方法
JP6577691B2 (ja) 2017-07-13 2019-09-18 協和キリン株式会社 抗ｂｒｉｌ抗体及び該抗体を用いたｂｒｉｌ融合タンパク質の安定化方法
EP3656791A4 (de) 2017-07-18 2021-03-31 Kyowa Kirin Co., Ltd. Anti-humane monoklonale ccr1-antikörper
WO2019022163A1 (ja) 2017-07-26 2019-01-31 Ｓｐｉｂｅｒ株式会社 改変フィブロイン
CN111094571B (zh) 2017-09-01 2023-10-27 国立大学法人新潟大学 龙涎香醇的有效制备方法
US11773180B2 (en) 2017-11-08 2023-10-03 Kyowa Kirin Co., Ltd. Bispecific antibody which binds to CD40 and EpCAM
WO2019117208A1 (ja) 2017-12-12 2019-06-20 協和発酵キリン株式会社 抗ｂｍｐ１０抗体及び該抗体を有効成分とする、高血圧および高血圧性疾患に対する治療剤
EP3816291A4 (de) 2018-06-26 2022-03-16 Kyowa Kirin Co., Ltd. Antikörperbindung an chondroitinsulfat-proteoglycan-5
KR20210027295A (ko) 2018-06-26 2021-03-10 쿄와 기린 가부시키가이샤 세포 부착 분자3에 결합하는 항체
JP7506607B2 (ja) 2018-12-28 2024-06-26 協和キリン株式会社 ＴｆＲに結合するバイスペシフィック抗体
WO2020145363A1 (ja) 2019-01-09 2020-07-16 Ｓｐｉｂｅｒ株式会社 改変フィブロイン
US20220033870A1 (en) 2019-01-31 2022-02-03 Spiber Inc. Method for producing recombinant protein
US20220259328A1 (en) 2019-05-15 2022-08-18 Kyowa Kirin Co., Ltd. Bispecific antibody binding to cd40 and fap
TW202108625A (zh) 2019-05-15 2021-03-01 日商協和麒麟股份有限公司 與cd40及gpc3結合之雙專一性抗體
TW202140561A (zh) 2020-02-14 2021-11-01 日商協和麒麟股份有限公司 與cd3結合之雙特異性抗體
US20230128695A1 (en) 2020-03-16 2023-04-27 Spiber Inc. Synthetic Polymer and Method for Producing Same, Molding Material, and Molded Body
CA3229748A1 (en) 2021-08-26 2023-03-02 Akifumi Kato Bispecific antibody that binds to cd116 and cd131

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU542264B2 (en) * 1979-06-01 1985-02-14 G.D. Searle & Co. Plasmid vectors
US4431739A (en) * 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
JPS5962527A (ja) * 1982-09-30 1984-04-10 Eisai Co Ltd 成人ｔ細胞白血病関連抗原の製造方法
JPS6061534A (ja) * 1983-09-16 1985-04-09 Kyowa Hakko Kogyo Co Ltd 成人ｔ細胞白血病ウイルス抗原ペプチド
EP0152030A3 (de) * 1984-02-03 1986-08-13 Juridical Foundation Japanese Foundation for Cancer Research Adult-T-Zell-Leukemiavirus-Antigenpolypeptid
US4724258A (en) * 1984-02-03 1988-02-09 Juridical Foundation, Japanese Foundation For Cancer Research Adult T cell leukemia virus antigen polypeptide
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
JPH0762034B2 (ja) * 1984-10-05 1995-07-05 富士レビオ株式会社 Ａｔｌｖ抗原活性を有する蛋白及びその製造法
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease

Also Published As

Publication number Publication date
US4939094A (en) 1990-07-03
DE3671244D1 (de) 1990-06-21
JP2564268B2 (ja) 1996-12-18
US5082776A (en) 1992-01-21
EP0214555A1 (de) 1987-03-18
CA1306209C (en) 1992-08-11
EP0214555B1 (de) 1990-05-16
JPS6248699A (ja) 1987-03-03

Similar Documents

Publication Publication Date Title
DE214555T1 (de) Fusionspolypeptid mit antigener wirkung.
HUT63652A (en) Process for producing cd44 surface protein variants, dna sequences encoding them and antibodies against them, as well as their application in diagnosis and therapy
HU9600692D0 (en) Human metabotropic glutamate receptor subtypes (hmr4, hmr6, hmr7) and related dna compounds
CA2020668A1 (en) Fused or hybrid protein comprising viral antigen and lymphokine
CA2032153A1 (fr) Application de nouveaux fragments d'adn en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
DE3587422D1 (de) Fuer ein hirudinaehnliches protein kodierende dns-sequenz und verfahren zur herstellung eines solchen proteins.
IL107951A (en) Mammalian receptors for interleukin-10 (il-10)
AU1986588A (en) Growth hormone receptor
DE262192T1 (de) Verfahren und mittel zur herstellung eines proteins mit dergleichen igg-spezifizitaet wie protein g.
AR017510A1 (es) Polinucleotido aislado o recombinante, vector de expresion, celula huesped, metodo para preparar un polipeptido antigenico, metodo y equipo para ladeteccion de un polinucleotido, compuesto de union, metodo de empleo del compuesto de union, polipeptido antigenico aislado o substancialmente puro, ymet
WO1999015666A3 (en) Macrophage derived chemokine (mdc), mdc analogs, mdc inhibitor sustances, and uses thereof
EP1626096A3 (de) In vitro Verfahren zum Detektieren einer zellproliferativen Krankheit, welches einen zum Fibroblastenwachstumsfaktor homologen Faktor 1 (FHF-1) involviert
AU8127494A (en) Chimeric proteins comprising borrelia polypeptides: uses therefor
ES555124A0 (es) Procedimiento de preparar particulas que contienen secuencias de aminoacidos y que tienen propiedades inmunogenas
DE69030615D1 (de) Neue Polypeptide, DNA-Sequenzen, die deren Expression erlauben, Verfahren zur Vorbereitung und Verwendung
IL92669A (en) TGF beta 1/beta 2: a chimeric transforming growth factor-beta
ES8609360A1 (es) Procedimiento para preparar peptidos
DE151475T1 (de) Adult-t-zell-leukemiavirus-antigenpolypeptid.
EP0562508A3 (en) Protein with bone formation ability and process for its production
DE152076T1 (de) Derivat des adult-t-zell-leukemiavirus-antigenpeptids.
DE146944T1 (de) Menschliches gamma-interferonpolypeptidderivat.
ATE127478T1 (de) Onkogen kodierendes polypeptid, das wachstumsfaktoraktivität besitzt, verfahren zu seiner herstellung und verwendung.
CA2024063A1 (en) Antibodies directed against nerve growth factor-like peptides
AU5315790A (en) Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by p. falciparum at the sporozoite stage and in the hepatocytes
EP0418626A3 (en) Fused proteins and production thereof